FGF2 and rheumatoid arthritis: In addition, MSCs have been used as a suitable gene therapy vectors for in vivo delivery of any therapeutic molecules, such as human soluble tumor necrosis factor receptor II (hsTNFR), interleukin-10 (IL10), and basic fibroblast growth factor (BFGF), demonstrating a promising therapeutic efficacy of genetically engineered MSCs in rheumatoid arthritis (RA) and spinal cord injury (SCI) [19–21].